CORRECTION: On Friday, Xenetic Biosciences Q4 GAAP EPS $(0.77) Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
CORRECTION: On Friday, Xenetic Biosciences Q4 GAAP EPS $(0.77) Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
Xenetic Biosciences(納斯達克股票代碼:XBIO)公佈的季度虧損爲每股0.77美元,比分析師普遍預期的0.87美元(0.87美元)高出11.49%。這比去年同期每股虧損1.00美元(1.00)增長了23%。該公司公佈的季度銷售額爲671,960美元,比分析師普遍預期的68萬美元低1.18%。這比去年同期的486,970美元的銷售額增長了37.99%。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧